Cargando…

Redox State of Human Serum Albumin and Inflammatory Biomarkers in Hemodialysis Patients with Secondary Hyperparathyroidism During Oral Calcitriol Supplementation for Vitamin D

BACKGROUND: Hemodialysis (HD) patients with secondary Hyperparathyroidism (s-HPT) are exposed to increased inflammation and oxidative stress. In HD patients, oxidized albumin is a reliable marker of oxidative stress and its clinical significance has been rarely studied. OBJECTIVE: The objective of t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nasif, Wesam A., Mukhtar, Mohammed H., El-Emshaty, Hoda M., Alwazna, Ahmed H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Open 2018
Materias:	Medicinal Chemistry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198414/ https://www.ncbi.nlm.nih.gov/pubmed/30450134 http://dx.doi.org/10.2174/1874104501812010098

Ejemplares similares

Serum Cytokine of IL-10 and IL-12 in Chronic Liver Disease: The Immune and Inflammatory Response
por: El-Emshaty, Hoda Mohamed, et al.
Publicado: (2015)

Mechanism of calcitriol regulating parathyroid cells in secondary hyperparathyroidism
por: Xiang, Zeli, et al.
Publicado: (2022)

Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients
por: Zheng, Cai-Mei, et al.
Publicado: (2018)

Comparison between Calcitriol and Calcitriol Plus Low-Dose Cinacalcet for the Treatment of Moderate to Severe Secondary Hyperparathyroidism in Chronic Dialysis Patients
por: Lee, Yueh-Ting, et al.
Publicado: (2013)

A Novel Rat Model of Vitamin D Deficiency: Safe and Rapid Induction of Vitamin D and Calcitriol Deficiency without Hyperparathyroidism
por: Stavenuiter, Andrea W. D., et al.
Publicado: (2015)

Hemodialysis patients’ preferences for the management of secondary hyperparathyroidism
por: Hauber, Brett, et al.
Publicado: (2017)

“Calcitriol” Is Not Synonymous with “Vitamin D”
por: Kimball, Samantha M., et al.
Publicado: (2012)

Cost-effectiveness analysis of intravenous paricalcitol vs. oral calcitriol in the treatment of hyperparathyroidism secondary to chronic kidney disease
por: Cardoso, Marilia Mastrocolla de Almeida, et al.
Publicado: (2022)

Paricalcitol versus Calcitriol + Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease in China: A Cost-Effectiveness Analysis
por: Zhang, Zhuolin, et al.
Publicado: (2021)

Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients
por: Shigematsu, Takashi, et al.
Publicado: (2018)

Cholecalciferol Additively Reduces Serum Parathyroid Hormone and Increases Vitamin D and Cathelicidin Levels in Paricalcitol-Treated Secondary Hyperparathyroid Hemodialysis Patients
por: Zheng, Jing-Quan, et al.
Publicado: (2016)

Effects of Vitamin D Supplementation on IGF-1 and Calcitriol: A Randomized-Controlled Trial
por: Trummer, Christian, et al.
Publicado: (2017)

Effect of calcitriol supplementation and tail suspension on serum biomarkers of bone formation in rats
por: Hashemian, Seyed Jafar, et al.
Publicado: (2015)

Parathyroidectomy Is Associated with Reduced Mortality in Hemodialysis Patients with Secondary Hyperparathyroidism
por: Ma, Tsung-Liang, et al.
Publicado: (2015)

PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism
por: Akizawa, Tadao, et al.
Publicado: (2016)

Parathyroidectomy Versus Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients
por: Alvarado, Luis, et al.
Publicado: (2022)

Paricalcitol in hemodialysis patients with secondary hyperparathyroidism and its potential benefits
por: Chen, Xiu, et al.
Publicado: (2021)

Effects of Zinc supplementation on serum copper to Zinc and CRP to albumin ratios in hemodialysis patients
por: Hajji, Marwa, et al.
Publicado: (2021)

The Effect of Vitamin C on Parathyroid Hormone in Patients on Hemodialysis With Secondary Hyperparathyroidism: A Double Blind, Placebo-Controlled Study
por: Biniaz, Vajihe, et al.
Publicado: (2013)

Efficacy of microwave ablation for severe secondary hyperparathyroidism in subjects undergoing hemodialysis
por: Diao, Zongli, et al.
Publicado: (2016)

Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients
por: Cunningham, John, et al.
Publicado: (2019)

Fibrous dysplasia in maxilla in a patient on hemodialysis with severe secondary hyperparathyroidism
por: Yang, Hui-Hsin, et al.
Publicado: (2022)

Coagulation and fibrinolysis in hyperparathyroidism secondary to vitamin D deficiency
por: Elbers, Laura P B, et al.
Publicado: (2018)

Contribution of dysregulated serum magnesium to mortality in hemodialysis patients with secondary hyperparathyroidism: a 3-year cohort study
por: Kurita, Noriaki, et al.
Publicado: (2015)

Vitamin D Metabolite Profile in Cholecalciferol- or Calcitriol-Supplemented Healthy and Mammary Gland Tumor-Bearing Mice
por: Anisiewicz, Artur, et al.
Publicado: (2020)

Treatment with cinacalcet increases plasma sclerostin concentration in hemodialysis patients with secondary hyperparathyroidism
por: Kuczera, Piotr, et al.
Publicado: (2016)

An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism
por: Block, Geoffrey A., et al.
Publicado: (2019)

Etelcalcetide in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism. Multicenter Study in “Real Life”
por: Russo, Domenico, et al.
Publicado: (2019)

One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism
por: Bushinsky, David A, et al.
Publicado: (2019)

One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism
por: Bushinsky, David A, et al.
Publicado: (2019)

Predictive factors requiring high-dose evocalcet in hemodialysis patients with secondary hyperparathyroidism
por: Tokumoto, Masanori, et al.
Publicado: (2022)

Observation of the efficacy of parathyroidectomy for secondary hyperparathyroidism in hemodialysis patients: a retrospective study
por: Qiu, Wenqiang, et al.
Publicado: (2023)

Hemodialysis patients with low serum parathyroid hormone levels have a poorer prognosis than those with secondary hyperparathyroidism
por: Yu, Yue, et al.
Publicado: (2020)

Vitamin D, the Vitamin D Receptor, Calcitriol Analogues and Their Link with Ocular Diseases
por: Caban, Miłosz, et al.
Publicado: (2022)

The effects of calcitriol with calcium carbonate supplementation on inflammatory biomarkers in chronic kidney disease patients’ with low vitamin D
por: Mustafar, Ruslinda BT, et al.
Publicado: (2014)

The Emerging Role of Nutritional Vitamin D in Secondary Hyperparathyroidism in CKD
por: Lu, Chien-Lin, et al.
Publicado: (2018)

Evocalcet with vitamin D receptor activator treatment for secondary hyperparathyroidism
por: Shigematsu, Takashi, et al.
Publicado: (2022)

Calcitriol/calcifediol ratio: An indicator of vitamin D hydroxylation efficiency?
por: Pasquali, Marzia, et al.
Publicado: (2015)

Relationship between serum parathyroid hormone levels and abdominal aortic calcification in patients starting hemodialysis who have never taken calcium tablets, calcitriol, or vitamin D analogs
por: He, Jin, et al.
Publicado: (2022)

Managing hyperparathyroidism in hemodialysis: role of etelcalcetide
por: Eidman, Keith E, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bfqjd45a424fdqqvc38p7kjhau